Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a Once-Daily pill help asian adults win the battle against obesity?

NCT ID NCT07775404

Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 20, 2026 · Last updated Aug 28, 2026 · Updated 3 times

Summary

This phase 3 trial is testing whether an experimental once-daily tablet called elecoglipron can help Asian adults with obesity or overweight lose weight, when combined with diet and exercise. The study includes people with or without type 2 diabetes. Participants will receive either elecoglipron or a placebo for about a year, and researchers will measure changes in body weight and waist size. The goal is to see if this pill can be a safe and effective tool for weight management.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Elecoglipron, an experimental once-daily tablet, taken alongside diet and exercise.
What this could lead to
If successful, elecoglipron could offer a new daily pill to help people with obesity or overweight achieve meaningful weight loss, potentially improving related health conditions.
What could go wrong
This is a phase 3 trial, but results are not yet known. The drug may not prove more effective than placebo, and side effects are possible. Success in this Asian population may not generalize to other groups.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 351 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2026

Expected to finish

Apr 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult participant aged 18 years or older at the time of informed consent. * Body mass index (BMI) at screening of: * 28 kg/m\^2 or higher, or * 24 kg/m\^2 to less than 28 kg/m\^2 with at least 1 weight-related comorbidity. * Stable body weight (self-reported or documented) for 90 days prior to the screening visit (± 5% body weight change) * History of at least 1 self-reported unsuccessful dietary effort to lose body weight. * Participants with type 2 diabetes mellitus, if enrolled, and have HbA1c from 6.5% to less than 10.0% at screening. Exclusion Criteria: * Any of the following medical history, laboratory values, or complications related to diabetes: * T1DM * HbA1c ≥ 10% (86 mmol/mol) at the screening visit * Currently receiving, or anticipated to receive, therapeutic intervention for diabetic retinopathy and/or macular edema. * Have had more than one episode of severe hypoglycemia within 180 days prior to the screening visit, or has a history of hypoglycemia unawareness or poor recognition of hypoglycemic symptoms. * History of acute (unless due to previously resolved gallstone pancreatitis and post-cholecystectomy) or chronic pancreatitis. * History/family history (first degree biologic relatives) of medullary thyroid cancer or multiple endocrine neoplasia type 2.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Obesity are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight type 2 diabetes mellitus Weight Loss

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Obesity Overweight

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    48 sites in 5 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Research Site

    NOT_YET_RECRUITING

    Baotou, 014040, China

  • Research Site

    NOT_YET_RECRUITING

    Beijing, 100044, China

  • Research Site

    NOT_YET_RECRUITING

    Beijing, 100050, China

  • Research Site

    NOT_YET_RECRUITING

    Beijing, 102218, China

  • Research Site

    NOT_YET_RECRUITING

    Changde, 415000, China

  • Research Site

    NOT_YET_RECRUITING

    Changsha, 410015, China

  • Research Site

    NOT_YET_RECRUITING

    Changzhou, 213000, China

  • Research Site

    RECRUITING

    Chengdu, 611130, China

  • Research Site

    NOT_YET_RECRUITING

    Hefei, 230601, China

  • Research Site

    NOT_YET_RECRUITING

    Huangshi, 435000, China

  • Research Site

    RECRUITING

    Jincheng, 048000, China

  • Research Site

    NOT_YET_RECRUITING

    Jinzhou Shi, 121001, China

  • Research Site

    NOT_YET_RECRUITING

    Langfang, 065000, China

  • Research Site

    NOT_YET_RECRUITING

    Luoyang, 471009, China

  • Research Site

    NOT_YET_RECRUITING

    Meihekou, 135022, China

  • Research Site

    NOT_YET_RECRUITING

    Nanjing, 210011, China

  • Research Site

    NOT_YET_RECRUITING

    Nanyang, 473000, China

  • Research Site

    NOT_YET_RECRUITING

    Nanyang, 473009, China

  • Research Site

    NOT_YET_RECRUITING

    Shanghai, 201199, China

  • Research Site

    NOT_YET_RECRUITING

    Shantou, 515065, China

  • Research Site

    NOT_YET_RECRUITING

    Shenyang, 110004, China

  • Research Site

    NOT_YET_RECRUITING

    Shenyang, 110023, China

  • Research Site

    NOT_YET_RECRUITING

    Shijiazhuang, 050001, China

  • Research Site

    WITHDRAWN

    Wuhan, 430010, China

  • Research Site

    NOT_YET_RECRUITING

    Wuhu, 241004, China

  • Research Site

    NOT_YET_RECRUITING

    Xianyang, 712000, China

  • Research Site

    NOT_YET_RECRUITING

    Xuzhou, 221000, China

  • Research Site

    NOT_YET_RECRUITING

    Yan’an, 716000, China

  • Research Site

    NOT_YET_RECRUITING

    Yueyang, 414000, China

  • Research Site

    NOT_YET_RECRUITING

    Zhumadian, 463000, China

  • Research Site

    NOT_YET_RECRUITING

    Zibo, 255499, China

  • Research Site

    RECRUITING

    Hong Kong, 999077, Hong Kong

  • Research Site

    NOT_YET_RECRUITING

    Randwick, 2031, Hong Kong

  • Research Site

    NOT_YET_RECRUITING

    Alor Star, 5460, Malaysia

  • Research Site

    NOT_YET_RECRUITING

    Kuala Lumpur, 59100, Malaysia

  • Research Site

    NOT_YET_RECRUITING

    Kuching, 93586, Malaysia

  • Research Site

    NOT_YET_RECRUITING

    Putrajaya, 62250, Malaysia

  • Research Site

    NOT_YET_RECRUITING

    Sarawak Miri, 98000, Malaysia

  • Research Site

    NOT_YET_RECRUITING

    Seremban, 70300, Malaysia

  • Research Site

    NOT_YET_RECRUITING

    Seri Manjung, 32040, Malaysia

  • Research Site

    NOT_YET_RECRUITING

    Sungai Buloh, 47000, Malaysia

  • Research Site

    NOT_YET_RECRUITING

    Davao City, PH-8000, Philippines

  • Research Site

    NOT_YET_RECRUITING

    Iloilo City, 5000, Philippines

  • Research Site

    NOT_YET_RECRUITING

    Manila, 1000, Philippines

  • Research Site

    NOT_YET_RECRUITING

    Bangkok, 10400, Thailand

  • Research Site

    NOT_YET_RECRUITING

    Bangkok, 10700, Thailand

  • Research Site

    NOT_YET_RECRUITING

    Chiang Mai, 50200, Thailand

  • Research Site

    NOT_YET_RECRUITING

    Phutthamonthon, 73170, Thailand

  • Research Site

    NOT_YET_RECRUITING

    Songkhla, 90110, Thailand

More trials for these conditions

Other studies related to the condition(s) this trial covers.